Navigation Links
Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
Date:7/20/2009

London, July 20 /PRNewswire/ -- There has been a recent upsurge in Merger & Acquisition (M&A) activities in the pharmaceutical and biotechnology space. While the economic downturn and related credit crunch has had an impact, this alone cannot account for the recent M&A mania, which has including four mega M&As in the first half of 2009.

(Logo:http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"The real intention behind these mergers remains a question, as past mergers have not yielded substantial value addition in terms of R&D productivity," says Frost & Sullivan Senior Research Analyst Ranjith Gopinathan.

To look at these Mergers & Acquisitions in the Pharmaceutical and Biotechnology industry, the Healthcare Group at Frost & Sullivan will be hosting a complimentary Analyst Briefing Presentation on Tuesday, 28th July 2009, at 2 p.m. BST/ 1 p.m. GMT.

Highlights of this briefing will include an analysis of the factors contributing to the increasing consolidation in the market, the impact of the economic downturn, as well as funding sources for biotech companies. The briefing will also look at key restraints for M&A activities in the pharma-biotech industry and provide a future M&A outlook. The discussion will benefit venture capitalists, investment banks, pharma and biotech companies as well as academic institutions.

"The global downturn's detrimental impact on funding availability coupled with an average 30 per cent decline in the value of biotech firms, means that outright acquisitions rather than complex licensing deals are an attractive proposition," concludes Gopinathan.

To participate in this briefing, please email Patrick Cairns at

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
2. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
3. Pharmacyclics Announces Subscription Price for Rights Offering
4. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
5. Simcere Pharmaceutical Group Notice of Annual General Meeting
6. Amylin Pharmaceuticals to Webcast Second Quarter Results
7. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
8. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
9. ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. ParagonRx Creates New Website Featuring REMS Help Center for Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... - Continued Advancement Toward ...   Shire (LSE: SHP, NASDAQ: SHPG ... March 31, 2015. Financial Highlights Q1 ... Total revenues $1,488 million +11% +15% Non GAAP operating ... from continuing operations $475 million +55% Non GAAP EBITDA ...
(Date:4/30/2015)... 2015 SureClinical, a leader in cloud-based ... has joined SureClinical’s executive team as Chief Financial Officer. ... technology executive with over 25 years in leadership roles ... , Ms. Morris joins SureClinical from Marrone Bio Innovations ... CFO of MBI from its founding in 2006 until ...
(Date:4/29/2015)... 29, 2015 SPIE DSS, ... on the East Coast, reaffirmed its value last week ... developers, and industry suppliers to meet and advance the ... applications. , The event included 55 conferences in two ... sensing and imaging -- and an exhibition showcasing 382 ...
(Date:4/29/2015)... CENTENNIAL, Colo. , April 29, 2015 /PRNewswire-USNewswire/ ... largest providers of cartilage, cellular, bone, skin and ... wound care to advance patient healing, announced the ... The Centers for Medicare & Medicaid Services (CMS) ... graft, from the low-cost to the high-cost category ...
Breaking Biology Technology:Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29Julie I. Morris Joins SureClinical as Chief Financial Officer 2SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4AlloSource Announces New Possibilities In Wound Care 2
... Inc. (Nasdaq: MEDX ) announced today that ... be the subject of poster presentations at the Annual ... being held April 18-22, 2009 in Colorado:, ... "A Phase I, open-label, dose-escalation, multi-dose study of MDX-1401 ...
... Symbol: MSEDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today announced financial and operational results ... has demonstrated the ability to safely affect MS progression ... results of the Canadian/European trial (MAESTRO-01) in the second ...
... Patents in Each of the Three Critical Areas of ... Corporation, a leading developer of targeted, systemic RNA interference ... and Trademark Office (USPTO) has issued the company a ... of a potent small interfering RNA (siRNA) sequence. ...
Cached Biology Technology:Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research 2BioMS Medical Announces 2008 Year End Results 2BioMS Medical Announces 2008 Year End Results 3BioMS Medical Announces 2008 Year End Results 4BioMS Medical Announces 2008 Year End Results 5BioMS Medical Announces 2008 Year End Results 6BioMS Medical Announces 2008 Year End Results 7BioMS Medical Announces 2008 Year End Results 8BioMS Medical Announces 2008 Year End Results 9BioMS Medical Announces 2008 Year End Results 10BioMS Medical Announces 2008 Year End Results 11Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence 2
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... Inc. (NASDAQ: AWRE ), a leading supplier of ... announced that Edmund C. Reiter has resigned, effective April 1, ... the board of the company citing personal reasons.   ... Counsel have been named co-CEOs and co-Presidents on an interim ...
... 2011 The Center for Engineering in Medicine (CEM) ... Hospital (MGH), a Harvard Teaching Hospital -- has announced ... in conjunction with event organizer Horizon House Ltd.  The ... School on July 14-15, and expects to draw over ...
... MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, ... bioimplants processed from human amniotic membrane, announced today the ... biologic implant specifically processed to offer a wide variety ... also announces the hiring of Frank Burrows as its ...
Cached Biology News:Aware, Inc. Announces Resignation of Chief Executive Officer 2Aware, Inc. Announces Resignation of Chief Executive Officer 3Massachusetts General Hospital Center Reignites Methods in Bioengineering Conference 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 3MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 4
... The Varian 500-MS LC Ion Trap ... high-throughput LC/MS analysis where sensitivity, reliability ... 500-MS provides a robust platform for ... mass resolution, and mass stability reflect ...
... Ventilates and removes chemical ... of exhaust. Bonded charcoal filters ... impellers ensure safe exhaust flow ... 15" access opening. Includes air ...
... benchtop ductless exhaust hood ventilates and ... indoor release of exhaust. Bonded charcoal ... 28" of vertical clearance (with access ... polypropylene spill tray; options include final ...
...
Biology Products: